◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Takeda Pharmaceutical Company Limited (4502) Net Income 2023–2026

Name: Takeda Pharmaceutical Company Limited (4502) net income history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-11

Takeda Pharmaceutical Company Limited annual net income for fiscal 2026 was -JPY 152.4 billion, compared with JPY 107.9 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

4502 Annual Net Income

Net Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Net Income	(JPY 152.4B)	JPY 107.9B	JPY 144.1B	JPY 317.0B

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

4502 Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Net Income	JPY 113.2B	(JPY 368.5B)	JPY 103.6B	(JPY 11.8B)	JPY 124.2B

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

4507 Net Income — Shionogi & Co., Ltd.
4523 Net Income — Eisai Co., Ltd.
4151 Net Income — Kyowa Kirin Co., Ltd.
4506 Net Income — Sumitomo Pharma Co., Ltd.
1276 Net Income — Jiangsu Hengrui Pharmaceuticals Co.,Ltd
4540 Net Income — Tsumura & Co.

More 4502 metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All 4502 financial statements → Interactive 4502 charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.